Prasugrel + Clopidogrel

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease

Trial Timeline

Feb 1, 2010 → Jun 1, 2010

NCT ID

NCT01014624

About Prasugrel + Clopidogrel

Prasugrel + Clopidogrel is a approved stage product being developed by Daiichi Sankyo for Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01014624. Target conditions include Coronary Artery Disease.

What happened to similar drugs?

20 of 20 similar drugs in Coronary Artery Disease were approved

Approved (20) Terminated (2) Active (0)

✅EvolocumabHeartFlowApproved

✅Clopidogrel treatment groupYuhanApproved

✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved

✅statins, ezetimibe + Combination therapyYuhanApproved

✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved

✅PrasugrelDaiichi SankyoApproved

✅30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01327534	Phase 3	Completed	May 1, 2011	Jul 1, 2013	Myocardial Infarction
NCT01260584	Approved	Completed	Nov 1, 2010	Sep 1, 2011	Coronary Artery Disease
NCT01107912	Phase 1	Completed	Mar 1, 2010	Oct 1, 2011	Coronary Artery Disease
NCT01107925	Phase 1	Completed	Mar 1, 2010	Aug 1, 2011	Coronary Artery Disease
NCT01014624	Approved	Completed	Feb 1, 2010	Jun 1, 2010	Coronary Artery Disease
NCT00910299	Phase 2	Terminated	Jul 1, 2009	Apr 1, 2011	Coronary Artery Disease (CAD)
NCT00830960	Phase 3	Completed	Feb 1, 2009	Jun 1, 2010	Acute Coronary Syndrome
NCT00642174	Phase 2	Completed	Apr 1, 2008	Jan 1, 2009	Diabetes Mellitus
NCT00385944	Phase 2	Completed	Mar 1, 2007	Oct 1, 2007	Acute Coronary Syndrome
NCT00097591	Phase 3	Completed	Nov 1, 2004	Jul 1, 2007	Coronary Arteriosclerosis

Competing Products

20 competing products in Coronary Artery Disease

See all competitors

Product	Company	Stage	Hype Score
Rosuvastatin 40mg + Placebo	HeartFlow	Pre-clinical	27
Evolocumab	HeartFlow	Approved	29
High intensity lipid lowering	HeartFlow	Pre-clinical	20
Exenatide	Eli Lilly	Phase 3	40
Clopidogrel treatment group	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibe	Yuhan	Approved	43
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)	Yuhan	Phase 3	40
statins, ezetimibe + Combination therapy	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrel	Daiichi Sankyo	Approved	43
clopidogrel + prasugrel	Daiichi Sankyo	Phase 1	21
Prasugrel	Daiichi Sankyo	Approved	43
ADP receptor inhibitors	Daiichi Sankyo	Pre-clinical	26
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel + Clopidogrel	Daiichi Sankyo	Phase 2	35
prasugrel + clopidogrel	Daiichi Sankyo	Phase 1	29
Triple oral lipid lowering treatment	Daiichi Sankyo	Phase 3	47
Placebo + Prasugrel	Daiichi Sankyo	Phase 3	40
30-day DAPT + Guideline-directed therapy	Daiichi Sankyo	Approved	50